Linkedin
RLS logo_header
Linkedin

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

“This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients,” said Ryan Fukushima, CEO, Data & Apps at Tempus. “We’ve spent years configuring our Lens Platform to seamlessly leverage our library of de-identified multimodal data with the necessary AI computing power to train and fine-tune specific models for healthcare. Working with the great scientists at Merck, we have exciting opportunities to translate the insights from AI models into precision medicine strategies and improve patient outcomes across oncology and beyond.”

Read the full story on "Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine"

Share:

More News

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

“From the outset, our goal has been to build a discovery engine that systematically unlocks high-value, challenging targets and delivers first-in-class precision medicines,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. “This collaboration lets us scale that engine alongside Novartis’ world-class development capabilities and global reach, so we

Independent DMC recommended continuation of Ph 3 OVATION 3 trial of IMNN-001 + SOC neoadjuvant and adjuvant chemo in 1L ovarian cancer

“We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer,”

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Ph 1/2 Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

“VS-7375 has demonstrated anti-tumor activity across multiple dose levels and tumor types, encouraging signals from rational combination strategies, and a favorable safety profile that improves meaningfully beyond the first treatment cycle, underscoring its potential to be not only the best-in-class oral KRAS G12D inhibitor, but also the preferred treatment option

FDA Accepts RP1 BLA Resubmission for Advanced Melanoma

“We are pleased that the FDA has demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need for advanced melanoma patients and support from the broader melanoma community,” said Sushil Patel, Ph.D., CEO of Replimune. “We look forward to a productive